Beximco Pharma to launch affordable generic of breakthrough cystic fibrosis drug

Beximco Pharmaceuticals Ltd has said it will launch an affordable generic version of Vertex Pharmaceuticals’ breakthrough cystic fibrosis (CF) drug Trikafta, offering hope to thousands of CF patients who currently lack access to treatment worldwide.

The company will produce the drug under the trade name Triko, according to a press release received on Saturday.

Triko will be priced at $6,375 per child per year, compared with the US list price of $370,000 for the original brand Trikafta.

The drug, expected to be available for purchase and supply from spring 2026, will enable 58 children to be treated for the price of treating one child with Vertex’s version.

Beximco is also launching Bexdeco, a generic version of ivacaftor -- one of the components of Triko -- priced at $5 per tablet.

Beximco Pharmaceuticals Chief Operation Officer Rabbur Reza said, “We believe our much affordable generic version of Trikafta will have a transformative impact on thousands of patients living with CF who are currently deprived of treatment due to the significant cost burden.”